EARTH LIFE SCIENCES INC
CLTSDrugs in Pipeline
19
Phase 3 Programs
4
Upcoming Catalysts
4
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
4 upcoming, 1 past
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
Prostate Cancer
18F-Fluciclovine PET CT
Cancer of the Prostate
rhPSMA-7.3 (18F) Injection
Prostate Cancer
18F fluciclovine
Brain Metastases
Arm A: 177Lu rhPSMA-10.1
Prostate Cancer
18F-rhPSMA-7.3 (Posluma)
Prostate Cancer (Post Prostatectomy)
18F-fluciclovine PET Scan
Metastatic Castration-resistant Prostate Cancer
FACBC PET-CT
Prostate Cancer
Androgen Deprivation Therapy (ADT) +/- bicalutamide
Intermediate Risk Prostate Cancer
18F-Fluciclovine
Brain Metastases
Flotufolastat F18
Prostatic Neoplasms
Actinium (225Ac) rhPSMA-10.1
Metastatic Castration-resistant Prostate Cancer
Furosemide
Prostate Adenocarcinoma
Leuprolide
Prostate Cancer
[18F]FPyQCP
Colorectal Cancer
Prednisone
Prostate Adenocarcinoma
Lutetium (177Lu) rhPSMA-10.1 Injection
Prostate Cancer
[68Ga]BED003
Colorectal Cancer
Fluorine F 18 Flotufolastat
Prostate Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent | Phase 3 | Prostate Cancer | - | - |
18F-Fluciclovine PET CT | Phase 3 | Cancer of the Prostate | - | - |
rhPSMA-7.3 (18F) Injection | Phase 3 | Prostate Cancer | - | - |
18F fluciclovine | Phase 3 | Brain Metastases | - | - |
Arm A: 177Lu rhPSMA-10.1 | Phase 2 | Prostate Cancer | - | - |
18F-rhPSMA-7.3 (Posluma) | Phase 2 | Prostate Cancer (Post Prostatectomy) | - | - |
18F-fluciclovine PET Scan | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
FACBC PET-CT | Phase 2 | Prostate Cancer | - | - |
Androgen Deprivation Therapy (ADT) +/- bicalutamide | Phase 2 | Intermediate Risk Prostate Cancer | - | - |
18F-Fluciclovine | Phase 2 | Brain Metastases | - | - |
Flotufolastat F18 | Phase 2 | Prostatic Neoplasms | - | - |
Actinium (225Ac) rhPSMA-10.1 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Furosemide | Phase 2 | Prostate Adenocarcinoma | - | - |
Leuprolide | Phase 2 | Prostate Cancer | - | - |
[18F]FPyQCP | Phase 2 | Colorectal Cancer | - | - |
Prednisone | Phase 2 | Prostate Adenocarcinoma | - | - |
Lutetium (177Lu) rhPSMA-10.1 Injection | Phase 2 | Prostate Cancer | - | - |
[68Ga]BED003 | Phase 2 | Colorectal Cancer | - | - |
Fluorine F 18 Flotufolastat | Phase 2 | Prostate Carcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in EARTH LIFE SCIENCES INC's drug pipeline?→
CatalystAlert tracks 19 drug candidates in EARTH LIFE SCIENCES INC's (CLTS) pipeline across Phase 3, Phase 2. Its lead program is 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EARTH LIFE SCIENCES INC's next FDA catalyst?→
EARTH LIFE SCIENCES INC's (CLTS) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLTS biotech catalysts?→
Add CLTS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EARTH LIFE SCIENCES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.